While there is no cure for multiple myeloma, treatment advancements in the last decade—from targeted drugs to stem cell transplants—have helped improve treatment outcomes and survival rates.

The following is a summary of “Time-dependent recovery of renal impairment in patients with newly diagnosed multiple myeloma, ...

Serum levels of polyclonal IgG, IgA and IgM are usually decreased in patients with multiple myeloma (MM); however ... positively associated with overall survival in patients with MM.

Traditionally carrying a dire prognosis, the treatment paradigm for multiple myeloma is changing, with CAR T therapies, ...

Despite these challenges, advances in the field are improving the outlook for people diagnosed with multiple myeloma. As evidence, the five-year overall survival rate in the United States has ...

Nichols said those factors and the length of time before diagnosis greatly impact mortality rates for individuals with multiple myeloma. “Five-year relative survival rates for multiple myeloma ...

In 1998, the five-year survival rate for multiple myeloma was 34.6%. That means that approximately 35 of 100 people with the disease were alive five years after their diagnosis. By the early 2000s ...

For patients with newly diagnosed multiple myeloma (NDMM) receiving dexamethasone induction, dose reductions do not ...

Opens in a new tab or window A novel combination for relapsed/refractory multiple myeloma produced ... month response rates were 86% and 77%. The estimated progression-free survival at 12 and ...

The company previously teased the overall survival (OS ... of relapsed or refractory multiple myeloma." The data reported at ASH revealed a 74% OS rate in the Blenrep plus BorDex (BVd) arm ...